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FIRST CLINICAL CASE REPORTIntraperitoneal meropenem for peritoneal dialysis peritonitis with Serratia
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Baker IDI, Melbourne, AustraliaAbstractA 67-year-old man developed Serratia marcescens peritonitis within a week of commencing peritoneal dialysis. Dialysate cultures isolated
multidrug-resistant S. marcescens, which was treated with intraperitoneal meropenem. This unusual case highlights the problem of
multidrug-resistant peritoneal dialysis infections and the potential viability of intraperitoneal meropenem as ambulatory peritonitis therapy.
New Microbes and New Infections © 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases.
Keywords: Intraperitoneal meropenem, non-Pseudomonas Gram-negative organisms, peritoneal dialysis, peritonitis, Serratia marcescens
Original Submission: 10 November 2015; Revised Submission: 15 January 2016; Accepted: 19 January 2016
Article published online: 27 January 2016Ne
Ne
Th
httCorresponding author: S. Wilson, Department of Nephrology,
The Alfred Hospital, 55 Commercial Road, Melbourne, Victoria 3004,
Australia
E-mail: s.wilson@alfred.org.auProportionally, non-Pseudomonas Gram-negative organisms ac-
count for approximately 20–30% of all peritonitis episodes
complicating peritoneal dialysis (PD) [1]. These infections are
typically more clinically severe and are associated with worse
outcomes, including a higher risk of hospitalization and death
[1,2]. Intraperitoneal (ip) antibiotic administration is favoured
over the intravenous (iv) route [3]; however, the rise of
multidrug-resistant organisms makes antibiotic choice increas-
ingly complex with few guideline recommendations beyond
aminoglycosides or third-generation cephalosporins.
We present the case of a patient who developed Serratia
marcescens peritonitis just days after commencing PD. This case
highlights that multidrug-resistant Gram-negative infections may
present at any time point in therapy and that ip administration
of meropenem is a viable alternative for the treatment of sus-
ceptible organisms.
A 67-year-old man with end-stage renal disease resulting
from immunoglobulin A nephropathy presented with PD
peritonitis 3 days after commencing nocturnal automated PD.w Microbe and New Infect 2016; 10: 84–86
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p://dx.doi.org/10.1016/j.nmni.2016.01.012Signiﬁcantly, he had no known bowel or structural urinary tract
pathology; nor did he have a history of recent hospitalization
beyond outpatient-based PD training. A Tenckhoff catheter had
been percutaneously placed without complications approxi-
mately 10 weeks before therapy commencement.
After only two overnight dialysis sessions, nonspeciﬁc
abdominal pain was noted, followed by the development of
turbid PD efﬂuent. Empirical antibiotic therapy with ip cepha-
zolin 1.5 g and gentamicin 0.6 mg/kg was initiated, in line with
hospital protocol. Peritoneal efﬂuent white cell count was
elevated, and cultures isolated S. marcescens with an inducible
β-lactamase in two separate samples (Fig. 1).
In the setting of signiﬁcant reluctance to administer pro-
longed gentamicin and logistical difﬁculties for the patient in
undertaking timely therapeutic drug monitoring, the antibiotic
prescription was changed to ip meropenem 1 g daily with the
intent of self-administration at home for a total 21-day course.
Surveillance PD efﬂuent conﬁrmed microbiologic clearance,
and PD has since continued uneventfully. Ip meropenem was
well tolerated and easily self-administered at home.
In PD patients in Australia and New Zealand, peritonitis
accounts for approximately 30% of technique failures and 21%
of infectious deaths [4].
S. marcescens, a Gram-negative, rod-shaped Enter-
obacteriaceae, is an uncommon human pathogen associated withEuropean Society of Clinical Microbiology and Infectious Diseases
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FIG. 1. Microbiology results from patient’s peritoneal ﬂuid. R, resistant;
S, sensitive.
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aemia, urinary tract infections and wound infections [5]. It is a
relatively rare cause of peritonitis, contributing to approxi-
mately 3% of peritonitis episodes in Australia in 2003–2006 [4].
S. marcescens is notoriously difﬁcult to treat because of an
intrinsic antimicrobial resistance proﬁle, and it is associated
with worse outcomes compared to other Gram-negative or-
ganisms [1,6].
A number of predisposing factors have been proposed to be
associated with Gram-negative peritonitis, including prior
administration of antimicrobial agents, immunosuppression,
diabetes, renal failure, steroid use, underlying gastrointestinal
pathology and malignancy [4]. In our patient, the only evident
risk factors were renal failure and exposure to the hospital
environment during PD training. Although the median time
from ﬁrst PD treatment to ﬁrst peritonitis in Australia is
approximately 20 months [7], this case is somewhat unusual in
that the patient had undertaken <5 days of therapy before
manifestation of peritonitis, strengthening the case for noso-
comial acquisition.
Data on the use of ip meropenem in humans remain limited
to case reports, typically in association with Pseudomonas spp.
infections [8]. No reference is made to the appropriateness or
efﬁcacy of ip meropenem in the latest iteration of the Inter-
national Society for Peritoneal Dialysis (ISPD) guidelines forNew Microbes and New Infections © 2016 The Authors. Published by Elsevier Ltd on behal
This is an open access artiPD-associated infections. Despite poor stability demonstrated
in the setting of elevated temperature and continuous iv in-
fusions [9], the stability of meropenem over 6 hours in a 2.5%
PD solution has been demonstrated [10]. Plasma area under the
curve over 24 hours appears to approximate that of the iv
route [11], though speciﬁc ip levels with respect to PD peri-
tonitis–relevant bactericidal concentrations have not been re-
ported. Particular concerns of drug intolerance during ip
administration have not been raised, and the entire treatment
course in our patient was well tolerated. Although it is a
microbiologically inappropriate choice as a ﬁrst-line agent, ip
meropenem represents an attractive proposition for multidrug-
resistant Gram-negative PD peritonitis. Administration prop-
erties are conducive to self-delivered therapy in the ambulatory
environment without the logistical burdens of frequent thera-
peutic drug level monitoring.
This case represents an unusually rapid onset of PD peri-
tonitis with a multidrug-resistant organism almost immediately
after commencing dialysis and demonstrates the feasibility of ip
meropenem in ambulatory PD peritonitis management. As
practical experience with ip meropenem accumulates, this
practice may merit discussion in the next iteration of the ISPD
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